Characterisation of P2Y receptor subtypes mediating vasodilation and vasoconstriction of rat pulmonary artery using selective antagonists.
AR-C118925XX
P2Y2 receptor
Pulmonary artery
Vasoconstriction
Vasodilation
Journal
Purinergic signalling
ISSN: 1573-9546
Titre abrégé: Purinergic Signal
Pays: Netherlands
ID NLM: 101250499
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
22
04
2022
accepted:
12
08
2022
pubmed:
27
8
2022
medline:
13
1
2023
entrez:
26
8
2022
Statut:
ppublish
Résumé
Pulmonary vascular tone is modulated by nucleotides, but which P2 receptors mediate these actions is largely unclear. The aim of this study, therefore, was to use subtype-selective antagonists to determine the roles of individual P2Y receptor subtypes in nucleotide-evoked pulmonary vasodilation and vasoconstriction. Isometric tension was recorded from rat intrapulmonary artery rings (i.d. 200-500 µm) mounted on a wire myograph. Nucleotides evoked concentration- and endothelium-dependent vasodilation of precontracted tissues, but the concentration-response curves were shallow and did not reach a plateau. The selective P2Y
Identifiants
pubmed: 36018534
doi: 10.1007/s11302-022-09895-x
pii: 10.1007/s11302-022-09895-x
pmc: PMC9832182
doi:
Substances chimiques
Uridine Triphosphate
UT0S826Z60
triphosphoric acid
NU43IAG5BC
Diphosphates
0
Adenosine Triphosphate
8L70Q75FXE
Uridine Diphosphate
58-98-0
Uridine
WHI7HQ7H85
Receptors, Purinergic P2Y1
0
Receptors, Purinergic P2Y2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
515-528Subventions
Organisme : British Heart Foundation
ID : FS/04/070
Pays : United Kingdom
Informations de copyright
© 2022. The Author(s).
Références
Int J Mol Sci. 2020 Sep 18;21(18):
pubmed: 32962005
Mol Pharmacol. 1996 Aug;50(2):224-9
pubmed: 8700127
J Pharmacol Exp Ther. 2012 Dec;343(3):755-62
pubmed: 22991416
Br J Pharmacol. 2021 Oct;178 Suppl 1:S157-S245
pubmed: 34529831
Biochem Pharmacol. 2004 May 1;67(9):1763-70
pubmed: 15081875
Br J Pharmacol. 2005 Sep;146(2):288-95
pubmed: 15997227
Eur J Appl Physiol. 2014 Sep;114(9):1995-2006
pubmed: 24929904
J Physiol. 2018 Jul;596(13):2491-2506
pubmed: 29790164
Br J Pharmacol. 2002 Jul;136(6):847-56
pubmed: 12110609
Br J Pharmacol. 1997 Feb;120(4):553-8
pubmed: 9051289
J Mol Cell Cardiol. 2016 Apr;93:1-11
pubmed: 26827897
Br J Pharmacol. 1998 May;124(1):1-3
pubmed: 9630335
J Med Chem. 2017 Oct 26;60(20):8425-8440
pubmed: 28938069
J Neurosci. 2012 Apr 11;32(15):5321-32
pubmed: 22496577
Br J Pharmacol. 1999 Feb;126(4):1009-17
pubmed: 10193782
Br J Pharmacol. 2020 Jun;177(11):2413-2433
pubmed: 32037507
J Pharmacol Exp Ther. 1989 Dec;251(3):1204-10
pubmed: 2600811
Respir Res. 2005 Oct 26;6:124
pubmed: 16250909
Biochem Pharmacol. 2004 Jul 1;68(1):113-24
pubmed: 15183123
Br J Pharmacol. 1991 May;103(1):1203-5
pubmed: 1652343
Arterioscler Thromb Vasc Biol. 2016 Aug;36(8):1598-606
pubmed: 27255725
Eur J Pharmacol. 2018 Oct 15;837:45-52
pubmed: 30170065
Naunyn Schmiedebergs Arch Pharmacol. 1999 Jan;359(1):7-10
pubmed: 9933143
Cardiovasc Res. 2010 Jan 1;85(1):204-13
pubmed: 19640930
Purinergic Signal. 2006 Jun;2(2):409-30
pubmed: 18404480
Pharmacol Rev. 2006 Sep;58(3):281-341
pubmed: 16968944
Eur J Pharmacol. 1999 Apr 9;370(2):139-43
pubmed: 10323262
Nat Med. 2006 Jan;12(1):133-7
pubmed: 16327800
BMC Cell Biol. 2017 Jan 17;18(Suppl 1):2
pubmed: 28124621
Am J Respir Crit Care Med. 2010 May 1;181(9):928-34
pubmed: 20093639
N Engl J Med. 1991 May 30;324(22):1539-47
pubmed: 2027358
Fundam Clin Pharmacol. 2018 Oct;32(5):499-506
pubmed: 29752814
Purinergic Signal. 2014;10(2):241-9
pubmed: 24310605
Mol Pharmacol. 2001 Sep;60(3):432-9
pubmed: 11502873
Cell Calcium. 2011 Apr;49(4):240-8
pubmed: 21414662
Pflugers Arch. 2008 Nov;457(2):281-91
pubmed: 18542991
Sci Signal. 2018 Dec 18;11(561):
pubmed: 30563865
Am J Physiol Heart Circ Physiol. 2004 Jul;287(1):H157-64
pubmed: 14962841
Auton Neurosci. 2015 Sep;191:2-15
pubmed: 26054908
Br J Pharmacol. 2006 Mar;147(5):569-74
pubmed: 16415908
Int Rev Cytol. 2004;240:31-304
pubmed: 15548415
Br J Pharmacol. 1996 Jun;118(3):704-10
pubmed: 8762097
J Cell Sci. 2012 Oct 1;125(Pt 19):4567-75
pubmed: 22767503
Sci Signal. 2015 Feb 17;8(364):ra17
pubmed: 25690012
J Med Chem. 1999 Jan 28;42(2):213-20
pubmed: 9925726
Bioorg Med Chem Lett. 2017 Nov 1;27(21):4849-4853
pubmed: 28958619
Am J Physiol. 1987 Feb;252(2 Pt 2):H434-8
pubmed: 3812755
Future Med Chem. 2013 Mar;5(4):431-49
pubmed: 23495690
Br J Pharmacol. 2021 Oct;178 Suppl 1:S27-S156
pubmed: 34529832
Circ Res. 2011 Jun 24;109(1):80-5
pubmed: 21546608
J Clin Invest. 2015 Aug 3;125(8):3077-86
pubmed: 26168216
Purinergic Signal. 2021 Mar;17(1):9-23
pubmed: 33527235
Circ Res. 2000 Sep 1;87(5):385-91
pubmed: 10969036
Br J Pharmacol. 1996 Jul;118(6):1415-20
pubmed: 8832066
J Am Heart Assoc. 2020 Sep 15;9(18):e017404
pubmed: 32867554
Br J Pharmacol. 2002 Nov;137(5):637-46
pubmed: 12381677
Trends Pharmacol Sci. 1995 May;16(5):168-74
pubmed: 7624972
Am J Physiol. 1996 Dec;271(6 Pt 2):H2717-22
pubmed: 8997335
Circ Res. 1982 Oct;51(4):439-47
pubmed: 7127680
Br J Pharmacol. 1998 May;124(1):5-12
pubmed: 9630336
Adv Exp Med Biol. 2017;1051:107-122
pubmed: 29134605
Br J Pharmacol. 2021 Feb;178(3):489-514
pubmed: 33125712
Purinergic Signal. 2020 Sep;16(3):453-461
pubmed: 32862324
Eur J Pharmacol. 2010 Dec 15;649(1-3):342-8
pubmed: 20868665
Br J Pharmacol. 1994 Nov;113(3):853-60
pubmed: 7858877
Mol Pharmacol. 1998 Dec;54(6):1118-23
pubmed: 9855642
Br J Pharmacol. 1995 Feb;114(4):846-50
pubmed: 7773545
Mol Pharmacol. 2003 Jul;64(1):104-12
pubmed: 12815166
Biochem Pharmacol. 2008 Nov 15;76(10):1201-13
pubmed: 18809389
Purinergic Signal. 2017 Mar;13(1):89-103
pubmed: 27766552
Circ Res. 1986 Mar;58(3):319-30
pubmed: 3013455
Br J Pharmacol. 2019 Aug;176(16):2894-2904
pubmed: 31116875
Pharmacol Ther. 2018 Oct;190:24-80
pubmed: 29660366
FASEB J. 2007 Feb;21(2):577-85
pubmed: 17167068
Am J Physiol Heart Circ Physiol. 2003 Aug;285(2):H693-700
pubmed: 12689860